Log in to search using one of your social media accounts:

 

American Society for Radiation Oncology Updates Insurance Coverage Recommendations for Proton Therapy

Proton beam therapy model policy recommends expanded access to advanced radiation therapy treatment for cancer patients ARLINGTON, Va., July 13, 2017 -- (Healthcare Sales &Marketing Network) -- The American Society for Radiation Oncology (ASTRO) has i... Devices, Oncology ASTRO , proton beam, proton therapy, radiotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

(Northwestern Memorial HealthCare) The Northwestern Medicine Chicago Proton Center will host over 200 leading clinicians, physicists and researchers in the growing field of proton therapy at the 4th Annual Particle Therapy Co-Operative Group North-America (PTCOG-NA) Conference, being held Oct. 23-25, 2017 at the Swiss ô tel Chicago. Conference participants will share the latest clinical, scientific and industrial developments in particle beam therapy, an advanced form of radiation therapy using beams of protons to destroy cancer cells and diseased tissue.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Medical software and equipment company Elekta has signed separate deals with Ion Beam Applications and Brainlab to share and integrate their technologies. In the memorandum of understanding with Ion Beam Applications, the two companies agreed to collaborate on investment in software development and the sale and marketing of each other’s products through a joint portfolio. Elekta specializes in technological solutions for improving, prolonging and saving the lives of patients with cancer and brain disorders, while IBA develops solutions for the diagnosis and treatment of cancer. Specifically, the companies plan to foc...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Wall Street Beat Elekta Source Type: news
Abstract PURPOSE: To compare heart and cardiac substructure radiation exposure using intensity-modulated radiotherapy (IMRT) vs. proton beam therapy (PBT) for patients with mid- to distal esophageal cancer who received chemoradiation therapy. METHODS AND MATERIALS: We identified 727 esophageal cancer patients who received IMRT (n=477) or PBT (n=250) from March 2004 to December 2015. All patients were treated to 50.4Gy with IMRT or to 50.4 cobalt Gray equivalents with PBT. IMRT and PBT dose-volume histograms (DVHs) of the whole heart, atria, ventricles, and four coronary arteries were compared. For PBT patient...
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
Over the last few decades, advances in radiation therapy technology have markedly improved radiation delivery. Advancements in treatment planning with the development of image-guided radiotherapy and techniques such as proton therapy, allow precise delivery of high doses of radiation conformed to the tumor. These advancements result in improved locoregional control while reducing radiation dose to surrounding normal tissue. The radiologic manifestations of these techniques can differ from radiation induced lung disease seen with traditional radiation therapy. Awareness of these radiologic manifestations and correlation wit...
Source: Journal of Thoracic Imaging - Category: Radiology Tags: Symposium Review Articles Source Type: research
CONCLUSION: Model and dose uncertainty highly influence the accuracy of model-based patient selection for proton therapy. A reduction of NTCP-model uncertainty is necessary to reach more accurate model-based patient selection. PMID: 28828923 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
CONCLUSION: For the studied liver case, intrafractional motion did not reduce the modulation of the RBE-weighted dose postulated by variable RBE models for proton treatments. PMID: 28828913 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Radiation therapy dose escalation using a simultaneous integrated boost (SIB) is predicted to improve local tumor control in esophageal cancer; however, any increase in acute hematologic toxicity (HT) could limit the predicted improvement in patient outcomes. Proton therapy has been shown to significantly reduce HT in lung cancer patients receiving concurrent chemotherapy. Therefore, we investigated the potential of bone marrow sparing with protons for esophageal tumors.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Physics Contribution Source Type: research
Conclusions For left-sided PMRT, passively scattered or PBS protons with or without DIBH improves homogeneity and cardiopulmonary sparing without compromise in target coverage compared with PWTF photons with DIBH. Furthermore, the addition of DIBH to proton therapy did not provide a significant dosimetric benefit.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
This study examined the impact of race and socioeconomic factors on the use of proton therapy in children with solid malignancies. METHODSThis study evaluated 12,101 children (age ≤ 21 years) in the National Cancer Data Base who had been diagnosed with a solid malignancy between 2004 and 2013 and had received photon‐ or proton‐based radiotherapy. Logistic regression analysis was used to evaluate patient, tumor, and socioeconomic variables affecting treatment with proton radiotherapy versus photon radiotherapy. RESULTSEight percent of the patients in the entire cohort received proton radiotherapy, and this proportion...
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
Conclusion For left-sided PMRT, passively scattered or PBS protons with or without DIBH improves homogeneity and cardiopulmonary sparing without compromise in target coverage compared to PWTF photons with DIBH. Furthermore, the addition of DIBH to proton therapy did not provide a significant dosimetric benefit.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Insurance | Marketing | Pharmaceuticals | Proton Therapy | Radiation Therapy